Acute Kidney Injury Clinical Trial
— HACSOfficial title:
Phase II Study of Heme Arginate in Patients Planned for Cardiac Surgery
A recent analysis of over 4500 cardiac surgical patients at the Royal Infirmary of Edinburgh
has confirmed that acute kidney injury (AKI) is not only a relatively common post-operative
complication but is associated with prolonged hospital stay, and increased risk of death.
There is currently no specific therapy available except supportive care.
In laboratory studies, heme arginate (HA), a drug licensed for human use, has been shown to
upregulate the anti-inflammatory enzyme hemeoxygenase-1 (HO-1) and protect aged mice from
acute kidney injury.
This study will bring this research into the human arena. It will aim to evaluate the
minimum effective dose of HA and verify its safety in this specific group of patients. This
will be the next step in investigating if HA could be a potential protective treatment for
reducing AKI in patients about to have cardiac surgery.
Patients who are due to have cardiac surgery and are aged 60 or above will be approached for
inclusion in the study. If agreeable, they will be randomly assigned to receive either HA at
a dose of 1mg/kg or 3mg/kg. There will be 10 patients in each group.
Blood tests will be taken just before the study drug is given, at 6 hours, 24 hours and 7
days post dose. These samples will be used to examine the effect of HA on HO-1 at different
doses, and will verify drug safety. Any adverse effects of the drug will be evaluated,
although HA has an excellent safety profile when used as it is currently licensed for acute
porphyria. Urine samples will also be collected to assess inflammation and quantify urinary
biomarkers of AKI. This will set the scene for a randomised clinical trial of HA in cardiac
surgical patients at high risk of AKI.
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | November 2014 |
Est. primary completion date | October 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 60 Years and older |
Eligibility |
Inclusion Criteria: Age =60 Planned for elective cardiac surgical procedure: - Aortic valve replacement - CABG Exclusion Criteria: Inability to give informed consent Hypersensitivity to HA Enrolment in other clinical trials Renal replacement therapy Planned for elective cardiac surgical procedure other than CABG or AVR (including combined CABG and AVR) Less than 2 weeks until planned cardiac surgery at time of study drug administration Active infection |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)
Country | Name | City | State |
---|---|---|---|
United Kingdom | Royal Infirmary of Edinburgh | Edinburgh | Midlothian |
Lead Sponsor | Collaborator |
---|---|
University of Edinburgh | Medical Research Council, NHS Lothian |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Upregulation of Heme oxygenase-1 protein expression in circulating monocytes | within 3 months of study completion | No | |
Secondary | Upregulation of heme oxygenase-1 messenger ribonucleic acid (mRNA) in circulating monocytes | within 3 months of completion | No | |
Secondary | Urinary biomarkers of acute kidney injury | Samples will be collected pre dose and at 24 hrs and 7 days to determine the effect (if any) of Heme arginate on levels of urinary biomarkers of AKI in order to inform future interventional trials | within 3 months of completion of study | No |
Secondary | Safety | This will be a composite outcome measure consisting of multiple routine measures of safety including adverse event reporting, and the biochemical and haematological data collected (eg renal function, liver function tests, full blood count) | at final study visit ie 7 days post dose (or at the resolution of any ongoing adverse event if this lasts longer than 7 days) | Yes |
Secondary | Heme oxygenase-1 (HO-1) Genotype | Patients will have their genotype for HO-1 gene recorded (for the long (L) or short (S) promoter region)- therefore they will be either LL, LS or SS. The study is not powered to detect any difference but will inform future studies. | within 3 months of study completion | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05538351 -
A Study to Support the Development of the Enhanced Fluid Assessment Tool for Patients With Acute Kidney Injury
|
||
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03938038 -
Guidance of Ultrasound in Intensive Care to Direct Euvolemia
|
N/A | |
Recruiting |
NCT05805709 -
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
|
N/A | |
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|
||
Recruiting |
NCT05897840 -
Continuous Central Venous Oxygen Saturation Measurement as a Tool to Predict Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients
|
N/A | |
Recruiting |
NCT04986137 -
Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Cirrhosis
|
||
Terminated |
NCT04293744 -
Acute Kidney Injury After Cardiac Surgery
|
N/A | |
Completed |
NCT04095143 -
Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury
|
||
Not yet recruiting |
NCT06026592 -
Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
|
||
Not yet recruiting |
NCT06064305 -
Transcriptional and Proteomic Analysis of Acute Kidney Injury
|
||
Terminated |
NCT03438877 -
Intensive Versus Regular Dosage For PD In AKI.
|
N/A | |
Terminated |
NCT03305549 -
Recovery After Dialysis-Requiring Acute Kidney Injury
|
N/A | |
Completed |
NCT05990660 -
Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery
|
N/A | |
Completed |
NCT04062994 -
A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
|
||
Terminated |
NCT02860130 -
Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
|
Phase 3 | |
Completed |
NCT06000098 -
Consol Time and Acute Kidney Injury in Robotic-assisted Prostatectomy
|
||
Not yet recruiting |
NCT05548725 -
Relation Between Acute Kidney Injury and Mineral Bone Disease
|
||
Completed |
NCT02665377 -
Prevention of Akute Kidney Injury, Hearttransplant, ANP
|
Phase 3 | |
Terminated |
NCT03539861 -
Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients
|
N/A |